Schizophrenia Burden of Illness

Schizophrenia is a debilitating illness with a significant economic burden

The psychotic features of schizophrenia typically emerge in the late-teens and the mid-30s, while onset prior to adolescence is rare1

  • Traditionally, earlier age at onset has been seen as a predictor of worse outcomes

Duration of untreated psychosis (DUP) may be 3.5X longer for adolescents than for adults with schizophrenia2

  • This suggests the importance of reducing DUP in youth because untreated psychosis can interfere with normative developmental processes in this age group

In a commercial claim-based analysis of patients 18-64 years of age, the average total PMPM cost with schizophrenia was 4X greater than in cohort without schizophrenia3

  • Mean PMPM cost was $1806 vs $419 for matched population (age and sex) without schizophrenia


References:

  1. American Psychiatric Association. Schizophrenia: In: Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013:99-105.
  2. Stentebjerg-Olesen M, Pagsberg AK, Fink-Jensen A, Correll CU, Jeppesen P. Clinical characteristics and predictors of outcome of schizophrenia-spectrum psychosis in children and adolescents: a systematic review. J Child Adolesc Psychopharmacol. 2016:26;410-427.
  3. Fitch K, et al. Resource utilization and cost in a commercially insured population with schizophrenia. Am Health Drug Benefits. 2014;7:18-26.